What Emeritus Research does

Emeritus Research is an Australian Phase I–IV outpatient clinical trial site services provider headquartered in Camberwell, Melbourne, with a second purpose-built facility in Sydney (Botany). Founded in 1999, the company conducts clinical trials for pharmaceutical sponsors and Contract Research Organizations (CROs) across more than 30 therapeutic areas, including infectious disease and vaccines (150+ studies), obesity and metabolic disease (24+ studies in five years), dermatology (50+ studies), rheumatology, cardiovascular, sexual health, and neurology. The company reports over 250 trials conducted and 8,000+ participants enrolled across both sites.

The underlying technology stack consists of a proprietary Clinical Trial Management System (CTMS) that supports operational tracking and enables 24-hour data entry across 98% of trials, alongside an exclusive partnership with Clinibase, a sister company described as Australia's largest full-service clinical trial recruitment provider. Clinibase delivers targeted digital recruitment campaigns with rigorous pre-screening. Emeritus also operates a dedicated investigator bench, including a world-leading rheumatologist CMO (Professor Paul Bird) and multiple Principal Investigators with specialty credentials spanning first-in-human, vaccine, dermatology, and metabolic disease trials.

The business model is professional services: revenue is generated through contracted clinical trial site services with pharmaceutical sponsors and CROs, with fees negotiated on a per-study basis and structured as per-patient costs, fixed site fees, or milestone-based payments. Go-to-market is primarily enterprise field sales via a dedicated Business Development team, targeting global big-pharma and biotech sponsors seeking Australian trial sites. Customer base includes 14+ named blue-chip pharmaceutical logos (Sanofi, GSK, J&J, Pfizer, Roche, Novartis, Eli Lilly, BMS, Gilead, Merck MSD, Amgen, Janssen, UCB, Celgene). The company is privately held under Emeritus Research Pty Ltd with no disclosed institutional funding or parent company.

Name

Emeritus Research

Legal name

Emeritus Research Pty Ltd

Website

https://emeritusresearch.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

51–100 employees

Short description

Emeritus Research is a privately held Australian clinical trial site operator running Phase I–IV outpatient trials in Melbourne and Sydney for global pharmaceutical sponsors and CROs across 30+ therapeutic areas, including vaccines, obesity, and dermatology, supported by an exclusive recruitment partnership with Clinibase.

Ownership category

akta.pro rank

Product category

Clinical Trial Site Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical and Diagnostic Laboratories (6215)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industries

Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG), Clinical Trial Pharmacy & IMP Management at Site (HLAGACAK)

Keywords

• Clinical trial services
• Phase I-IV trials
• Vaccine research
• Patient recruitment
• Therapeutic area research

Headquarters

HQ city

Camberwell

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Clinical Trial Site Services: Emeritus Research generates revenue by providing clinical trial site services to pharmaceutical sponsors and CROs. Services include conducting Phase I-IV outpatient clinical trials across multiple therapeutic areas, participant recruitment (via exclusive partnership with Clinibase), data management, and regulatory support. Revenue is earned through contracted clinical research services with fees typically structured as per-patient costs, fixed site fees, or milestone-based payments depending on study complexity and sponsor agreements.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Emeritus Research is a private clinical trial site services organization that conducts Phase I-IV outpatient clinical trials for pharmaceutical sponsors and CROs across purpose-built facilities in Melbourne and Sydney, Australia. The company delivers full-service trial management, participant recruitment (via exclusive partnership with Clinibase), data management, and regulatory support across 30+ therapeutic areas including infectious disease, vaccines, obesity/metabolic diseases, rheumatology, cardiovascular, dermatology/immunology, neurology, and sexual health.

Product overview

Emeritus Research operates as a single unified clinical research organization offering comprehensive Phase I–IV trial services across multiple therapeutic areas. The core offering consists of full-service clinical trial management delivered through purpose-built sites in Melbourne and Sydney, supported by an exclusive partnership with Clinibase for patient recruitment. The portfolio spans specialized research services across seven therapeutic areas: Vaccine Research (150+ studies), Metabolic Disease/Obesity (24+ trials), Sexual Health, Rheumatology, Cardiovascular, Dermatology/Immunology (50+ studies), and Neurology. The company differentiates through experienced investigators, rapid 24-hour data entry, and high participant retention rates (98% completion, 90%+ in obesity studies), providing biotech and pharma sponsors with a single trusted partner for Australian clinical development programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Services (Phase I-IV) Full-service clinical trial management delivering Phase I-IV outpatient trials from purpose-built sites in Melbourne and Sydney, combining experienced investigators with rapid 24-hour data entry across 98% of trials. Designed for global pharmaceutical sponsors and CROs seeking to run clinical studies in Australia.
• Patient Recruitment Services

Quantifiable outcome

• 98% of trials have 24-hour data entry turnaround
• +6 more outcomes

Named customers20 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• ClinibasecoreChannel Partner/ Reseller/ DistributorExclusive partnership with Clinibase, Australia's largest full service clinical trial recruitment provider and a sister company. Clinibase delivers large-scale, targeted digital recruitment campaigns designed to reach specific patient populations, with every lead carefully pre-screened before a clinic visit is booked. This ensures only well-qualified participants progress into studies. The partnership includes a seamless, sponsor-aligned pathway from first contact to first visit, with Clinibase functioning as the primary recruitment engine for Emeritus Research.

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Q-Pharm: Brisbane-based early-phase clinical trial unit specializing in healthy volunteer studies, vaccine trials, and first-in-human research; competes head-to-head with Emeritus for sponsor allocations in Australia.
• Linear Clinical Research: Perth-based Australian clinical trial site conducting Phase I-IV trials across multiple therapeutic areas; a direct competitor for sponsor placements in Australia and a comparable SMO with purpose-built facilities and early-phase capabilities.
• Nucleus Network: Australia's largest early-phase clinical trial organization with dedicated Phase I units in Melbourne and Brisbane; directly comparable to Emeritus for first-in-human, vaccine, and early-phase biotech trials targeting Australian sites.
• CMAX Clinical Research: Adelaide-based Phase I-II clinical trial facility focused on early-phase and first-in-human studies; a regional Australian SMO competing for similar biotech and pharma sponsor workloads.
• Paratus Clinical Research (formerly International Medical Research): Australian multi-site clinical research organization running Phase I-IV trials with sites across multiple states; an emerging peer scaling head-to-head with Emeritus for sponsor placements in dermatology, vaccines, and metabolic indications.

Others

• Charles River Laboratories: Preclinical and early-phase clinical research services provider including early-phase site operations; comparable as an adjacent player that competes for early-phase sponsor budgets and influences site selection strategy.

Broad incumbents

• ICON plc: Global CRO that owns dedicated clinical trial sites (e.g., PRA Health) and acts as a sponsor intermediary that books capacity at SMOs like Emeritus; comparable as a buyer-of-services and as a broader end-to-end alternative for sponsors.
• IQVIA: World's largest CRO with embedded site network and site-management offerings; competes indirectly with Emeritus both as a buyer of SMO capacity in Australia and as an integrated alternative for sponsors.
• Medpace: Mid-to-large global CRO with strong biotech sponsor relationships that frequently engage Australian SMOs; relevant comparable as a counterparty and as an integrated alternative to using a dedicated Australian SMO.
• Thermo Fisher Scientific (PPD): Global CRO and clinical research services provider post-PPD acquisition; relevant as both a buyer of Emeritus's SMO capacity and as a broader competitive offering for sponsors running Australian trials.

Market position

Weaknesses1 record

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/emeritusresear1

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Emeritus Research